NDA/Supplement #: 21-213
Drug: Mevacor™
OTC 20 mg
Sponsor: MERCK
Study: Label
Comprehension Study
Study Report Date: August
2004
Reviewer: Laura
Shay, RN, MS, C-ANP
Reviewing Division: HFD-560
Background
A label comprehension study was conducted for
nonprescription lovastatin 20 mg in June 2003.
This study was conducted following a number of qualitative and
quantitative pilot studies. The sponsor
states that the label used in this label comprehension study incorporates the
NCEP ATP III cholesterol treatment guidelines, advice and guidance from an
academic panel of lipid experts, and feedback from FDA (specifically the June
5, 2002 Advice Letter). This label comprehension
study was conducted using the package label (carton back panel) that was
studied in the Mevacor OTC consumer behavior study (actual use study) Protocol
084 (CUSTOM). The consumer behavior
study was in progress when the label comprehension study began. The label studied was submitted in the
Objectives
Primary Objective
·
Determine the percent of respondents who
demonstrate that they comprehend the Mevacor OTC package label used in the
CUSTOM study by being able to correctly answer questions about specific
elements as well as apply their understanding to “scenarios” that combine
multiple elements.
Secondary Objectives
·
Determine how well respondents correctly respond
to questions designed to try to measure self-selection.
·
Evaluate the results among low literacy respondents.
·
Evaluate the results among a combined subgroup
of non-Caucasian respondents.
Key factors on the label the
sponsor considered to be most important for consumers to understand:
·
Comprehension of what condition the product is
to be used for (Q7);
·
Scenarios that describe combinations of age,
gender, cholesterol levels, risk factors, and other factors that should alert
respondents to talk to their doctors before using the product or to not use it
at all (Q21);
·
Other medical conditions or medications that
require consultation with a health care professional prior to product use or
preclude use (Q22 and Q23);
·
Dosage
·
Scenarios that address comprehension of the
timing for follow-up cholesterol testing (Q35);
·
Scenarios that explore comprehension of the goal
message (Q37); and
·
Scenarios that describe events that might occur
during product usage that should indicate that they need to stop using the
product and/or talk with a doctor (Q38).
Other factors evaluated:
·
Active ingredient in the product (Q8);
·
Scenarios that address prerequisites for using
the product, specifically diet, exercise, and appropriate time frame for
testing cholesterol in order to decide whether or not to use the product (Q19);
·
Understanding that a person’s cholesterol level
will go back up if someone stops using the product (Q31 and Q32); and
·
Understanding that evening is the best time of
day to take it (Q33 and Q34).
Methodology
Study Design
The study was a “one-cell study” design with a
question-answer format conducted through a structured interview.
Sampling
The sample was a convenience sample recruited from shopping
malls. Respondents were screened in 25 geographically and
demographically dispersed malls across the country. The representative sample
was recruited first followed by the recruitment of additional low-literacy
subjects in 17 of the 25 screening sites.
No additional recruiting was required to augment the numbers of
Caucasian or non-Caucasian subjects.
Subjects selected to participate in the study were considered
“cholesterol-concerned respondents”. To
determine if a respondent was “cholesterol-concerned” the screener showed the
respondent a concept board for Mevacor OTC (without price or any label specific
information) and asked how likely they would be to consider using it. Respondents who gave one of the first three
responses in the 5-point scale (definitely, probably, might, might not,
probably not, definitely not) were invited to participate in the study. All subjects were given the Rapid Estimate of
Adult Literacy in Medicine (REALM) test in order to determine the total number
of low-literate subjects. Those who
missed 6 or more words in the REALM test (corresponding to an 8th
grade reading level or lower) were classified as low-literate. Respondents who were able to participate the
day of the screening received $20. Respondents who had to return on another day
received an additional $5 to compensate for the travel expense.
The following is the “Concept Board” used to screen for “cholesterol-concerned”
respondents:
Comment:
The concept board did
not provide specific inclusion or exclusion criteria for the study or specifics
on the label so it would not have introduced bias into the label comprehension
study.
Data collection
Study respondents were placed alone in a private room with
an empty package of Mevacor OTC. They
were instructed to review the package for as long as they needed (generally
about 5 minutes). The respondents were then interviewed using the Mevacor OTC
package as a reference. Respondents were
asked several times during the procedure if they needed time to re-read the
package label or get up and stretch their legs.
Each interview averaged less than 45 minutes.
The Interview Questionnaire
The interview questionnaire contained 81 questions. The interview questions are in the attachment
at the end of this review. This review
will concentrate only on the results of those questions designed to evaluate
comprehension. Several of the “questions,”
in fact, are statements or instructions read to the respondents by the
interviewer, not questions. For example,
questions 1-3 on the questionnaire stated the following:
The sponsor states that an attempt was made to address all
the communication elements on the package label, however, because the label
contains a lot of information, efforts were made via the study and
questionnaire design to try to minimize respondent fatigue. The sponsor described this process as the
following:
-Each respondent saw half of the
total number of selection scenarios (5 of the 10 total scenarios; Q21).
-Each respondent saw about half of
the total number of real pre-existing conditions (3 or 4 of the total 7: Q23).
-Reasons
for wrong self-selection decisions were, however, captured by asking several general questions (Q77-81).
The flow of the interview questions were described by the
sponsor as the following:
Data analysis
Five cohorts were analyzed: (1) total representative sample,
(2) Caucasian, (3) non-Caucasian,
(4) non-low-literacy, and (5) low-literacy.
Primary analysis was conducted on the percent of respondents
in the total representative sample who gave “correct plus acceptable” and
“correct” responses. The
“representative” sample did not include respondents who were augmented for low
literacy. The total low literacy group
(those in the representative sample plus the augmented respondents) was
compared to the remaining respondents in the representative sample (“non-low
literacy subgroup”). The total
non-Caucasian subgroup was compared to the remaining respondents in the total
representative sample (“Caucasian subgroup”).
The sponsor determined that a response was considered “acceptable” if it
did not specifically adhere to the label directions but would pose no potential
safety risk. In addition, many of the
“acceptable” responses involve talking with doctor. The sponsor submitted the
following table to outline the response classifications:
Self-selection was analyzed in the 5 cohorts. This was accomplished by the following: Each respondent’s self-reported medical
history, medical conditions, demographics, and knowledge of their own
cholesterol numbers (Q50-75) were analyzed against their response to the
questions about whether or not it would be appropriate to start using this drug
(Q9-17). Subjects who self-selected incorrectly were
questioned further in an attempt to understand the reasons for their
inappropriate response (Q77-81).
Because each questionnaire contained half of the total
number of selection scenarios (5 of the 10 total scenarios; Q21) and half of
the total number of real pre-existing conditions (3 or 4 of the
total 7; Q23) the sponsor described the analysis of their
data in the following way: “As noted in “Overall Design”, some questions were
answered by only half of the total sample.
With this in mind, the following table was created (Table 4: Confidence
intervals at various sample sizes). It
is based on the confidence interval for a normal approximation to the binomial
distribution, to indicate statistical precision associated with responses of
50%. The formula was used is:
p + Z √ p(1-p)”
n
Comments on the
Methodology:
The FDA statistician will be reviewing the statistical plan for this
study. His results were not available at
the time of this review.
The sponsor did not provide specific inclusion or exclusion criteria
for the study. The only eligibility
criterion described by the sponsor was that they included subjects who were
considered “cholesterol-concerned respondents”.
There was no mention of visual or language requirements as an inclusion
or exclusion criteria, even though potential study participants were asked if
they wore reading glasses.
The objectives are appropriate to evaluate label comprehension and
self-selection, however, the ability to self-select should be listed as a
primary not a secondary objective.
Prompting the respondent to re-read the label is not naturalistic. It would be have been more appropriate to
determine if consumers were able to grasp the appropriate information in order
to use the product safely and effectively by referring to the label at their
own discretion without being prompted.
The sponsor indicated that there is a lot of information on the
label. In a naturalistic setting, a
consumer would need to read and understand all the important communication
objectives on the label in order to self-select appropriately and use the
product correctly. The sponsor states
that because there is a lot of information on the label they designed the study
to minimize fatigability during the research session. What we do not know from
this study is how fatiguing a consumer would find reading the label in its entirety.
The flow of the questions do not appear to bias the response. Overall the questions appear to be well written
and non-leading.
Results
Sample
A total of 696 respondents were recruited from the 25
geographic locations. The following
tables show the breakdown of the sample according to cohort, geographic
location, age, and gender.
Sample size of each cohort:
Total representative sample |
696 |
Total low-literacy in the representative sample |
111 |
Total number of augmented low-literate* |
92 |
Total number of non-low literate |
493 |
Total non-Caucasian from the representative sample |
207 |
Total Caucasian from the representative sample |
489 |
* In order to have an adequate number of low-literate
respondents, additional low-literate respondents were recruited. Therefore, it is important to note that in
all the tables, the total low-literacy sample and the total non-low literacy
sample will not equal the total representative sample.
Geographical Locations:
|
25 |
|
31 |
|
32 |
|
21 |
|
24 |
|
25 |
|
36 |
|
33 |
|
22 |
|
30 |
|
24 |
|
35 |
|
27 |
|
23 |
|
19 |
|
22 |
|
19 |
|
23 |
|
31 |
|
40 |
|
40 |
|
17 |
|
31 |
|
16 |
|
50 |
|
|
Sample Proportion
by Age and Gender:
|
Men |
Women |
Total % |
44 |
56 |
Age as % of Total Gender: |
|
|
18-34 |
25 |
24 |
35-44 |
23 |
21 |
45-54 |
21 |
21 |
55 and older |
30 |
35 |
% Age Breakdown of 55 and Older |
Men/Women |
|
55-59 |
10.6 |
|
60-64 |
7.8 |
|
65-69 |
5.2 |
|
70-74 |
2.7 |
|
75 or older |
4.9 |
|
55 or older unspecified |
1.6 |
|
Comment:
Approximately half the study participants were under age 45. The product is labeled for use in men 45 and
older and women 55 and older. Because
the sample contains a large number of younger participants it is not possible
to generalize these results to the target population. In
addition, less than 10% of participants were older than 65. This age group often has more difficulty acquiring
information on OTC labels, especially when the print is small. Therefore testing larger numbers in this age
group is important.1
The following are the results of this label comprehension
study. The results are presented in
relation to the corresponding study objective or key communication factors. As previously mentioned, not all “questions”
in the questionnaire are really questions, therefore only the bonafide questions
designed to evaluate comprehension will be reviewed. Tables with a table number identifier (e.g.
Table 14) are tables submitted by the sponsor.
Tables without a table number identifier are the reviewer’s summaries of
data submitted by the sponsor.
1 Wogalter, MS, & Vigilante, WJ. 2003.
Effects of label format on knowledge acquisition and perceived readability by
younger and older adults, Ergonomics,
46(4), 327-344.
·
Comprehension
of what condition the product is used for
Q7: “First, what is MEVACOR™OTC
used to treat?”
|
Total |
Caucasian |
Non-Caucasian |
Non-Low Literacy |
Low Literacy |
Sample size |
696 |
485 |
207 |
585 |
203 |
|
N % |
N % |
N % |
N % |
N % |
Correct* |
686 99 |
478 99 |
204 99 |
578 99 |
198 98 |
*Open ended question. The correct answers included: high
cholesterol, reduce cholesterol, lower cholesterol, treat bad cholesterol,
treat LDL, for cholesterol. Incorrect answers
included: treat high blood pressure and prevent heart attack.
Comment:
Results indicate that most of the respondents understood the indication
for Mevacor OTC.
·
Active
ingredient in the product
Q8: What is the
active ingredient in MEVACOR™OTC?
|
Total |
Caucasian |
Non-Caucasian |
Non-Low Literacy |
Low Literacy |
Sample size |
696 |
485 |
207 |
585 |
203 |
|
N % |
N % |
N % |
N % |
N % |
Correct* |
641 92 |
446 92 |
191 92 |
554 95** |
171 84** |
*Open ended question. Correct answers included: lovastatin or
lovastatin 20 mg.
**Statistically significant
difference at a 95% C.I. between Non-Low literacy and Low Literacy group
Comment:
Results indicate that a substantial majority of the respondents
understood that lovastatin is the active ingredient in Mevacor OTC.
·
Scenarios
that describe combinations of age, gender, cholesterol levels, risk factors and
other factors that should alert respondents to talk to their doctors before
using this the product or to not use it at all
·
Other
medical conditions or medications that require consultation with a health care
professional prior to product use or preclude use
Data for these communication
objectives are combined in the following tables (Tables 15-19) supplied by the
sponsor for Questions 21-23.
Scenarios for Question 21:
Answer choices: This person could
start using right away; before using, this person needs to ask a doctor or get
more information; this person should not use at all; or don’t know.
·
Francine
is 61 years old. Before using
MEVECOR™OTC, her LDL “bad” cholesterol is 150.
Her mother had a heart attack at age 59.
Assume Francine has no other reasons not to use this product today. (correct=could start using right away,
acceptable=needs to ask a doctor first or get more information)
·
Jane
is 60 years old. Before using
MEVACOR™OTC, her LDL “bad” cholesterol is 115.
She has high blood pressure. She
is not taking any prescription medicines.
Assume Jane has no other reasons not to use this product starting today.
(correct= needs to ask a doctor first or get more information, acceptable=this
person should not use at all)
·
Kathleen
is 58 years old. She doesn’t know her
LDL “bad” cholesterol or her HDL “good” cholesterol numbers. Her father had a heart attack when he was
47. Assume Kathleen has no other reasons
not to use this product starting today. (correct= needs to ask a doctor
first or get more information, acceptable=this person should not use at
all)
·
Steve
is 47 years old. Before using
MEVACOR™OTC, his LDL “bad” cholesterol is 140.
His HDL “good” cholesterol is 33.
Assume Steve has no other reasons not to use this product starting
today. (correct=could start using right away, acceptable=needs to
ask a doctor first or get more information)
·
Victor
is 59 years old. Before using
MEVACOT™OTC, his “bad” cholesterol is 145.
His HDL “good” cholesterol is 32.
Recently he had a muscle pain side effect taking cholesterol lowering
medicine and had to stop using it.
Assume Victor has no other reasons not to use this product starting
today. (correct=this person should not use at all, acceptable=
needs to ask a doctor first or get more information)
·
Brenda
is 68 years old. Before using
MEVACOR™OTC, her LDL “bad” cholesterol is 156.
Her father had a heart attack at the age of 50. Assume Brenda has no other reasons not to use
this product starting today. (correct=could
start using right away, acceptable=needs to ask a doctor first or get
more information)
·
Carol
is 72 years old. Before using
MEVACOR™OTC, her LDL “bad” cholesterol is 250.
She has high blood pressure. She
is not taking any prescription medicines.
Assume Carol has no other reasons no to use this product starting today.
(correct=this person should not use at all, acceptable= needs to
ask a doctor first or get more information)
·
David
is 46 years old. Before using
MEVACOR™OTC, his LDL “bad” cholesterol is 145.
His HDL “good” cholesterol is 32.
Assume David has no other reasons not to use this product starting
today. (correct=could start using
right away, acceptable=needs to ask a doctor first or get more
information)
·
Laurie
is 45 years old. Before using
MEVACOR™OTC, her LDL “bad” cholesterol is 155.
She has high blood pressure. She
is not taking any prescription medicines.
Assume Laurie has no other reasons not to use this product starting
today. (correct= needs to ask a
doctor first or get more information, acceptable=this person should not
use at all)
·
Rob
is 68 years old. Before using MEVACOR™OTC,
his LDL “bad” cholesterol is 160. His
father had a heart attack at the age of 45.
Rob is allergic to lovastatin.
Assume Rob has no other reasons not to use this product starting today. (correct=this person should not use at
all, acceptable= needs to ask a doctor first or get more information)
Comment:
Some
percentages and numbers in this sponsor’s table do not appear to add up. This is also true for some of the other
sponsor tables that follow in this review.
Comments:
These scenarios represent the section of the label called “How to decide if MEVACOR™OTC is right for
you”. The sponsor stated that this
section of the label is based on the ATP-III guidelines for determining risk
for coronary artery disease. The intent
is for the consumer to read the 4 columns in this section of the label in
sequence and, using this information, determine if they should or should not
take Mevacor OTC.
Table 16 provides data for only correct responses to these scenarios. The range of respondents who answered
correctly was 26-82 % with an average of 52.6%.
According to the questionnaire, a
correct response for Laurie, who is 45 years old, is “before using, this person
needs to ask a doctor first or get more information.” This response should not
have been considered correct. The correct
response should have been “this person should not use at all” because Laurie is
less than 55 years of age. If we adjust
the data to reflect the correct response, only 84 of the 348 respondents
answered correctly. This corresponds to
24% of the total which is less than half of the 57% reported in Table 16
above.
According to the questionnaire, a correct response for Jane, whose LDL
cholesterol is only 115, is “before using, this person needs to ask a doctor first
or get more information.” This response should not have been considered
correct. The correct response should
have been “this person should not use at all” because Jane’s LDL cholesterol is
less than 130. If we adjust the data to
reflect the correct response, only 107 of the 348 respondents answered
correctly. This corresponds to 31% of
the total which is well below the 54% reported in Table 16 above.
Table 15 provides the results when the acceptable results are added to
the correct results. This increases the
range to 71-97% with an average of 88.7%.
In most cases, the acceptable response was “needs to ask a doctor first
or get more information”. Because this
one answer combined two discretely different actions “ask a doctor” or “get
more information”, it is possible that respondents defaulted to this answer
because it provided them with several options.
If the two options were separate choices, the acceptable results may
have been different given that Kathleen was the only scenario requiring more
information.
The sponsor has analyzed the data for these scenarios and others in
such a way that simply by random guessing, respondents could end up with a
correct or acceptable answer 50% of the time.
This reviewer does not see validity in this analytical approach which
falsely elevates the appearance of comprehension.
In both tables there were few differences between cohorts.
Scenarios for Question 22:
Answer choices: This person could
start using right away; before using, this person needs to ask a doctor first;
or don’t know.
·
Al is using a nonprescription cough drop for a mild cough. (correct=this
person could use right away)
·
Sara takes a prescription medicine to lower her cholesterol. (correct=before using,
this person needs to ask a doctor first)
·
Doug takes a prescription medicine for his ulcer. (correct= before using, this person
needs to ask a doctor first)
·
Lisa has developed a case of hemorrhoids and has started to use
Preparation H for it. (correct= this person could use right away)
·
Linda takes a nonprescription fiber laxative for regularity this. (correct=person
could use right away)
·
Comment:
These
scenarios represent the “Warnings”
section of the label under the subsection “Ask your doctor or pharmacist before use if you are taking”.
Table 17 provides the data for correct answers to these scenarios. The results indicate that the respondents
understood the need to ask a doctor or pharmacist before taking Mevacor OTC if
someone is on a prescription medication (88-95%). However it appears that the respondents were
unclear on how to handle situations not specified on the label. In all the scenarios associated with the use
of specific types of non-prescription medications, only 50-77% understood that
these medications did not preclude them from starting Mevacor OTC “right away”.
Scenarios for Question 23:
Answer choices: This person could
start using right away; before using, this person needs to ask a doctor first;
this person should not use at all; or don’t know.
·
Peter gets gas
from over-eating once in a while.
(correct=this person could start using right away, acceptable=before
using, this person needs to ask a doctor first)
·
Barbara has liver
disease. (correct=this person should not use at all, acceptable=
before using, this person needs to ask a doctor first)
·
Luke had a stroke
several years ago. (correct= before using, this person needs to ask a
doctor first, acceptable= this person should not use at all)
·
John has occasional constipation. (correct=this person could start using right
away, acceptable=before using, this person needs to ask a doctor first)
·
Amanda’s triglycerides
are 450. (correct= before using, this person needs to ask a doctor
first, acceptable= this person should not use at all)
·
Helen is breast-feeding.
(correct=this person should not use at all, acceptable= before
using, this person needs to ask a doctor first)
·
Bill was camping in the woods and got a case of poison ivy. (correct=this person
could start using right away, acceptable=before using, this person needs
to ask a doctor first)
·
·
Mary had a heart
attack last year. (correct= before using, this person needs to ask a
doctor first, acceptable= this person should not use at all)
·
Cindy has diabetes.
(correct=this person should not use at all, acceptable= before
using, this person needs to ask a doctor first)
Comments:
These
scenarios represent the section of the label under Warnings. The scenarios
included specific medical contraindications listed on the label under the following
subheading:
·
“Do not use if” (these scenarios
include: liver disease, pregnant, and breast feeding)
·
“Do NOT use unless directed by your doctor
if you have”(these scenarios include stroke, high triglycerides 200-900
mg/dl, heart attack, and diabetes)
Medical
problems not contraindicated on the label were also included in the scenarios
(gas from food, poison ivy, and constipation.)
The
range of correct responses to the scenarios that represent the subheading “Do not use if” (these scenarios
include: liver disease, pregnant, and breast feeding) was 65-78%. No where under this subheading does it direct
the consumer to “ask a doctor”. Thus,
the sponsor’s plan to count this choice as “acceptable” is not
appropriate. It is impossible to know from a label
comprehension study if respondents would “ask a doctor”. The fact that most of the respondents who answered
incorrectly deferred to the response “before using, this person needs to ask a
doctor first” may have been the result of the multiple choice format. The use
of open-ended questions would have provided better insight into the
respondent’s ability to comprehend the important information listed in the Warnings section of the label.
The
sponsor refers to “real issues” as those medical contraindications listed on
the label and refers to “false issues” as those medical conditions not listed
on the label as contraindications. Table
19 provides data for only correct responses to these scenarios. The range of respondents who answered the
“real issues” correctly was 56-78% with an average of 67.3%. The range of
respondents who answered the “false issues” correctly was 47-72% with an
average of 63%. There was a
statistically significant difference between the low-literacy and non-Caucasian
cohorts and their respective comparator controls. Both scored lower for the “false issues”. Table 18 provides the “acceptable” results plus
the correct results. This increases the
range to 80-100% for the “real issue” responses with an average of 95% and
89-96% for the “false issue” responses with an average of 94%. In all cases, the “acceptable” response was
either “before using, this person needs to ask a doctor first” or “this person
should not use at all”.
·
Scenarios
that address prerequisites for using the product, specifically diet, exercise, and
appropriate time frame for testing cholesterol in order to decide whether or
not to use the product:
Scenarios for Question 19a and 19b:
Answer choices: true, false, or
don’t know
·
Alan
has never had his cholesterol tested. He
does not need to have his cholesterol tested before starting to use MEVACOR™OTC.
·
Ben
has been swimming laps regularly and watching his diet. His cholesterol has not gone down. It’s okay for him to use MEVACOR™OTC.
·
·
Janet
had her cholesterol tested 2 months ago.
It’s okay that she is using these numbers to help decide if MEVACOR™OTC
is right for her.
·
Melanie
does not need to try a healthy diet before starting MEVACOR™OTC because MEVACOR™OTC
will lower her cholesterol in place of the diet.
·
Sam
had his cholesterol tested 2 years ago.
It’s okay that he is using those numbers to help decide if MEVACOR™OTC
is right for him.
Comments:
Responses to these scenarios that address the prerequisites for using
this product (diet, exercise, and appropriate time frame for testing
cholesterol) were mixed. The respondents
scored well (81-95%) in their understanding that not having a cholesterol test
or having one taken 2 years ago is inadequate. The concept for the need to have
a fasting cholesterol was not well understood across all groups (68-78%) with
the Non-Caucasian group scoring the lowest (68%).
Perhaps the reason the respondents answered so poorly (59-65%) to the scenario
“Ben has been swimming laps regularly and watching his diet. His cholesterol has not gone down. It’s okay for him to use MEVACOR™OTC,” was
because it was poorly written. This
scenario provided inadequate
Respondents answered correctly 80-86% to the scenario regarding the
need to try eating a healthy diet before starting MEVACOR™OTC (Melanie). Although this percentage demonstrates a fairly
good understanding of this concept, this reviewer would hope for better
comprehension of this point. None of the
questions in this label comprehension study address the need to continue eating
a healthy (specifically a low fat) diet when using Mevacor OTC.
Scenarios for Question Q35
Answer choices: Get a cholesterol
test now, get a cholesterol test after a few more weeks, no need to get a
cholesterol test anytime soon, or don’t know.
Connie has been taking MEVACOR™OTC for
4 weeks
Dan has been taking MEVACOR™OTC for 8
weeks
Comment:
There were two scenarios in this question. These addressed when cholesterol levels
should be re-checked. These scenarios
only provide
Scenarios for Question Q37:
Question A for these scenarios communicates what the appropriate time is
to get a repeat cholesterol test.
Answer choices: Yes, Know, or
Don’t Know
Ø
After taking MEVACOR™OTC for 6 weeks, Eddie got a follow-up LDL test. His LDL test was 115. A-Did Eddie get a follow-up LDL at the appropriate time?
Ø
After taking MEVACOR™OTC for 3 weeks, Kevin got a follow-up LDL test. His LDL
test result was 137. A-Did Kevin get a follow-up LDL test at
the appropriate time?
Ø
After taking MEVACOR™OTC for 6 weeks, Sophie got a follow-up LDL test. Her LDL result was 158. A-
Did Sophie get a follow-up LDL test at the appropriate time?
|
Total |
Caucasian |
Non-Caucasian |
Non-Low Literacy |
Low Literacy |
Sample size |
222 |
161 |
60 |
190 |
71 |
Correct |
N % |
N % |
N % |
N % |
N % |
Eddie |
206 93 |
151 94 |
55 92 |
178 94 |
62 87 |
Sample size |
246 |
172 |
72 |
207 |
71 |
Correct |
N % |
N % |
N % |
N % |
N % |
Kevin |
196 80 |
141 82 |
54 75 |
169 82 |
52 73 |
Sample size |
228 |
152 |
75 |
188 |
61 |
Correct |
N % |
N % |
N % |
N % |
N % |
Sophie |
191 84 |
132 87 |
58 77 |
161 86 |
49 80 |
Comment:
According to responses to Eddie and Sophie, it appears that the
respondents understood that having a cholesterol re-checked at 6 weeks is
correct (77-94%). According to responses to Kevin, the respondents had lower
comprehension in understanding that having a cholesterol checked at 3 weeks is
incorrect (73-80%). This difference may
be the result of having the words “Test
at 6 weeks” clearly displayed on the label in bold print and underlined,
whereas the label does not mention what or what not to do at 3 weeks.
Q26: “First, what is MEVACOR™OTC supposed to do to a person’s LDL
Cholesterol?
|
Total |
Caucasian |
Non-Caucasian |
Non-Low Literacy |
Low Literacy |
Sample size |
696 |
485 |
207 |
585 |
203 |
|
N % |
N % |
N % |
N % |
N % |
Correct* |
684 98 |
479 99 |
201 97 |
576 98 |
198 97 |
*Open ended question. The correct answers included: lowers LDL/Bad
cholesterol/reduces it, lowers LDL/Bad cholesterol to below 130/129 or below,
keep it down, miscellaneous lowers LDL/Bad cholesterol comments.
Comment:
Results indicate that most of the respondents understood how Mevacor
OTC should affect the LDL cholesterol.
Scenarios for Question Q37: Question
B for these scenarios communicates understanding of cholesterol goal.
Answer choices: Yes, Know, or
Don’t Know
Ø
After taking MEVACOR™OTC for 6 weeks, Eddie got a follow-up LDL test. His LDL test was 115. Did Eddie’s follow-up
LDL test fall to the right level or not?
Ø
After taking MEVACOR™OTC for 3 weeks, Kevin got a follow-up LDL test. His LDL
test result was 137. Did Kevin’s follow-up LDL test fall to the
right level or not?
Ø
After taking MEVACOR™OTC for 6 weeks, Sophie got a follow-up LDL test. Her LDL result was 158. Did Sophie’s follow-up LDL test result fall
to the right level or not?
|
Total |
Caucasian |
Non-Caucasian |
Non-Low Literacy |
Low Literacy |
Sample size |
222 |
161 |
60 |
190 |
71 |
Correct |
N % |
N % |
N % |
N % |
N % |
Eddie |
192 86 |
144 89 |
48 80 |
166 87 |
58 82 |
Sample size |
246 |
172 |
72 |
207 |
71 |
Correct |
N % |
N % |
N % |
N % |
N % |
Kevin* |
11 4 |
6 3 |
5 7 |
9 4 |
2 3 |
Sample size |
228 |
152 |
75 |
188 |
61 |
Correct |
N % |
N % |
N % |
N % |
N % |
Sophie |
148 65 |
105 70 |
42 56 |
128 68 |
33 54 |
*The responses for Kevin to
question (B) were few because respondents who answered question (A) correctly
(73-82%) were not asked question (B).
Comment:
Results from these scenarios indicate that respondents understood when
LDL cholesterol decreased to the goal range with 80-90% correct responses to
Eddie. They did not understand, as well, when LDL
cholesterol did not reach the goal range (54-70% correct responses for Sophie).
Scenarios for Question Q37:
Question C for these scenarios communicates what an individual should do
based on their cholesterol results:
Ø
After taking MEVACOR™OTC for 6 weeks, Eddie got a follow-up LDL test. His LDL test was 115. Which statement on this
card best describes what Eddie should do next?
o Continue
to use MEVACOR™OTC and does not need to talk to a doctor.
o Continue
to use MEVACOR™OTC but must talk to a doctor.
o Stop
using MEVACOR™OTC. Does not need to talk
to a doctor.
o Stop
using MEVACOR™OTC. Must talk to a doctor.
o Don’t
know
Eddie |
Total |
Caucasian |
Non-Caucasian |
Non-Low Literacy |
Low Literacy |
Sample size |
222 |
161 |
60 |
190 |
71 |
|
N % |
N % |
N % |
N % |
N % |
Correct |
131 59 |
104 65 |
27 45 |
118 62 |
31 44 |
Net Correct* |
194 87 |
144 89 |
50 83 |
167 88 |
58 82 |
*Net correct answers included:
o Continue
to use MEVACOR™OTC and does not need to talk to a doctor. (correct)
o Continue
to use MEVACOR™OTC but must talk to a doctor. (acceptable)
o Stop
using MEVACOR™OTC. Must talk to a
doctor. (acceptable)
Ø
After taking MEVACOR™OTC for 3 weeks, Kevin got a follow-up LDL test. His LDL
test result was 137. Which statement on this care best
describes what Kevin should do next?
o Continue
to use MEVACOR™OTC and does not need to talk to a doctor.
o Continue
to use MEVACOR™OTC but must talk to a doctor.
o Stop
using MEVACOR™OTC. Does not need to talk
to a doctor.
o Stop
using MEVACOR™OTC. Must talk to a doctor.
o Don’t
know
Kevin |
Total |
Caucasian |
Non-Caucasian |
Non-Low Literacy |
Low Literacy |
Sample size |
246 |
172 |
72 |
207 |
71 |
|
N % |
N % |
N % |
N % |
N % |
Correct* |
NA* |
NA* |
NA* |
NA* |
NA* |
*NA (not applicable): If respondents answered the first
question (question A) in this scenario correctly (No) “Did Kevin get a
follow-up LDL test at the appropriate time, or not?” they were not asked this
question. Therefore, not answering this
question is considered correct.
Ø
After taking MEVACOR™OTC for 6 weeks, Sophie got a follow-up LDL test. Her LDL result was 158. Which statement on this care best describes
what Sophie should do next?
o Continue
to use MEVACOR™OTC and does not need to talk to a doctor.
o Continue
to use MEVACOR™OTC but must to talk to a doctor.
o Stop
using MEVACOR™OTC. Does not need to talk
to a doctor.
o Stop
using MEVACOR™OTC. Must talk to a doctor.
o Don’t know
Sophie |
Total |
Caucasian |
Non-Caucasian |
Non-Low Literacy |
Low Literacy |
Sample size |
228 |
152 |
75 |
188 |
61 |
|
N % |
N % |
N % |
N % |
N % |
Correct |
77 34 |
56 37 |
21 28 |
70 37 |
12 20 |
Net Correct* |
164 72 |
116 76 |
48 64 |
141 75 |
40 66 |
*Net correct included any of the following answers:
o Stop
using MEVACOR™OTC. Must talk to a
doctor. (correct)
o Continue
to use MEVACOR™OTC but must to talk to a doctor. (acceptable)
o Stop
using MEVACOR™OTC. Does not need to talk
to a doctor. (acceptable)
Comment:
Respondents did poorly
with these scenarios. A respondent had a
3 out of 5 (60%) chance of randomly providing an “acceptable” answer to these
questions. The range for correct
responses was 20-65%. The range for
acceptable plus correct responses was 64-89%.
The respondents scored poorly in their understanding of what to do if
the LDL does decrease to goal (below 130).
The range of correct responses for reaching goal (Eddie who’s LDL was
115), was 44-65%.
The range of correct
responses for not reaching goal (Sophie who’s LDL was 158), was even worse,20-37%. One of the answers for Sophie is “Stop
using MEVACOR™OTC. Must talk to a doctor.” Asking
your doctor may have been the answer chosen by many respondents if they did
not know because they
may have been embarrassed to admit that they did not know the answer. An open ended question would have been a
better way to test comprehension of this concept. The non-Caucasian and low-literacy cohorts scored
lower then the Caucasian and non-low literacy cohorts. What someone like Kevin,
who may have had a borderline post-treatment LDL should do, was not really
addressed.
Scenarios for
Question Q38:
Answer choices: Continue to use Mevacor OTC and does not
need to talk to a doctor; Continue to use Mevacor OTC, but must talk to a
doctor; Stop using Mevacor OTC, does not need to talk to a doctor; Stop using
Mevacor OTC, must talk to a doctor; or Don’t know.
·
Diane
has been taking MEVACOR™OTC for several weeks.
She didn’t do any unusual physical activity and isn’t feeling sick but
she has started to feel pain in her leg muscles. (correct= Stop using
Mevacor OTC, must talk to a doctor, acceptable= Continue to use Mevacor
OTC, but must talk to a doctor, acceptable= Stop using Mevacor OTC, does
not need to talk to a doctor)
·
Ellen has
been taking MEVACO™OTC for several weeks.
She took Tums for indigestion that she got from eating spicy foods. (correct=
Continue to use Mevacor OTC and does not need to talk to a doctor, acceptable=
Continue to use Mevacor OTC, but must talk to a doctor, acceptable= Stop
using Mevacor OTC, must talk to a doctor)
·
Harry
has been taking MEVACOR™OTC for several weeks.
He got caught in the rain and developed a mild cold. (correct=
Continue to use Mevacor OTC and does not need to talk to a doctor, acceptable=
Continue to use Mevacor OTC, but must talk to a doctor, acceptable= Stop
using Mevacor OTC, must talk to a doctor)
·
Bob
has been taking MEVACOR™OTC for several weeks.
One day he was digging in his garden and the next day his shoulders
ached. (correct= Continue to use Mevacor OTC and does not need to talk
to a doctor, acceptable= Continue to use Mevacor OTC, but must talk to a
doctor, acceptable= Stop using Mevacor OTC, must talk to a doctor)
·
Paul
has been takin MEVACOR™OTC for several weeks.
He was given a prescription antibiotic medicine for pneumonia. (correct=
Continue to use Mevacor OTC, but must talk to a doctor, correct= Stop
using Mevacor OTC, must talk to a doctor, acceptable= Stop using Mevacor
OTC, does not need to talk to a doctor)
·
Theresa
has been taking MEVACOR™OTC for several weeks.
At her yearly physical,
she was diagnosed with kidney
disease. (correct= Continue to use Mevacor OTC, but must talk to a
doctor, correct= Stop using Mevacor OTC, must talk to a doctor, acceptable=
Stop using Mevacor OTC, does not need to talk to a doctor)
Comments:
The respondents also
have a 3 out of 5 chance of having an “acceptable” response in these scenarios
or a 60% chance of randomly succeeding.
The range of correct responses for unexplained muscle pain was 74-81%
with an increase to 97-99% when “acceptable” and correct responses were added
together. It is incorrect to consider
the response to “Continue to use Mevacor OTC, but must talk to a doctor”
acceptable when individuals are instructed on the label to stop taking Mevacor
OTC if they have unexplained muscle pain. The fact that respondents had lower percentages
of correct scores for explained muscle pain (38-51%) indicates that most of the
respondents did not understand the difference between explained and unexplained
muscle pain.
Even when confronting
“a person develops a cold” scenario, consumers defaulted to the “talk to a
doctor” options. Only 60-69% answered
correctly (they do not need to talk to a doctor). This raises further question if respondents
are picking any answer that contains wording “talk to your doctor” because it
is a “safe response” rather than responding “I don’t know”.
The scores for correct
answers went up (87-89%) in response to being prescribed medicine for
pneumonia. This may be because the
correct answer to this question contained “talk to a doctor”. Again, this may reflect a “safe response” and
may not provide the necessary information to determine label comprehension
Overall, respondents
understood that that Mevacor OTC does not need to be stopped if an individual
develops kidney disease but they must talk to a doctor with 89-90% answering
correctly.
The sponsor supplied the following
table which addresses all of these communication objectives:
Comment:
Respondents demonstrated a good understanding of these concepts: the number of times a day Mevcacor OTC should
be taken (97-99% had a correct response; the time of day it should be taken (82-91%
had a correct response); and the number of tablets a day that it should be
taken (99% had a correct response).
Overall the respondents appeared to understand that they should not
increased their dose on their own(87-89% had a correct response). The respondents had a poor understanding of
what will happen if they stop taking Mevacor OTC (53-68%). This appears partly due to their inability to
find this concept on the label. The
number of respondents able to find this information on the label was only 60-70%. The low-literacy cohort had significantly
lower scores.
Q9: Using the package information
as the basis for your answer, could you, yourself, start to use MEVACOR™OTC
today, or not? (Answer choices: I could start using MEVACOR™OTC today, I must
not start using MEVACOR™OTC today, or Don’t know.
Q10: What specific information on
the package helped you decide that you (probe for answer given in question 9)
]Q11: Assuming you were interested
in trying MEVACOR™OTC, is there anything that you personally would do before
starting to use it, or not? (Answer choices: yes, no, wouldn’t use the product,
don’t know)
Q12: what would you do? What else?
Q13: How likely is it that you
would talk to your doctor about MEVACOR™OTC before starting to use it? (Answer
choices: very likely, somewhat likely, not too likely, not at all likely, or
don’t know)
Q39: Age
Q40: Ever had heart disease such
as a heart attack, angina, heart bypass surgery, or a balloon angioplasty for
your heart? Every had any kind of stroke, including mini-strokes and transient
ischemic attacks know as TIAs? Currently
have diabetes or high blood sugar?
Q41: Do you currently have liver
disease such as hepatitis, or other liver problems?
Q42: Are you, yourself, allergic
to lovastatin, which is the active ingredient in MEVACOR®?
Q43: Are you pregnant?
Q44: Are you currently practicing
any method of birth control?
Q45: Are you breast feeding a
baby?
Q46: Are you taking any prescription drugs to
lower you blood lipids, cholesterol or triglycerides?
Q47: Are you currently taking any
other prescription medicines, that is, medicines that have been prescribed by a
doctor?
Q49: Are you currently taking any
of the prescription medicines that are listed on this card?
Q50: Are you currently taking 1000
milligrams or more of niacin in order to lower cholesterol or not?
Per Agency request, the following
table supplied by the sponsor provides data on the number of respondents who self-selected
correctly, acceptably, or incorrectly based on their self-reported medical
history and demographics:
Comments:
Of the total
respondents, only 67% self-selected correctly.
The responses in each cohort were similar (65-67%). This percentage increases to 90% when “acceptable”
responses are added to correct responses.
Acceptable responses include: Can start MEVCAOR™OTC today (Q9) but
volunteered that they would ask their doctor when asked further (Q11-12), and
Don’t know (Q9) but volunteered that they would ask their doctor when asked
further (Q11-12). If a respondent does
not correctly comprehend the label but volunteers that he or she would “ask a
doctor” their response should not be considered “acceptable”. The fact that a participant volunteered, in
response to a probing question, that he or she would “ask a doctor” is
reflective of a behavior not measurable in this study and not the ability to
comprehend a label.
The sponsor supplied separate tables containing data for
respondents who reported having medical conditions or other contraindications
listed on the label. The tables are
presented in three sections according to the subheadings in which they appear
under the Warnings section of the label.
To assist in clarity of the review, the exact wording as it appears on
the label will also be presented.
The first subheading under the Warnings
section of the label is: “Do not use if”
§
Liver
Disease: Do NOT use if you have liver disease.
§
Do NOT use if you had any muscle pain, weakness
or tenderness from taking a cholesterol-lowering medicine.
§
Pregnant
or breast-feeding: Do NOT use if you are pregnant or breast-feeding.
§
Allergic
to lovastatin: Do NOT use if you know you are allergic to lovastatin or the
inactive ingredients in this medicine, as listed below.
The following tables supplied by
the sponsor provide data for respondents who self-selected correctly,
acceptably, or incorrectly based on reported medical conditions for which the
label states “Do not use if”. These
medical conditions in the tables include liver disease, allergy to lovastatin,
pregnancy, breast feeding, or muscle problem from a prior cholesterol
medication.
Comments:
Liver disease: The total number of respondents reporting
that they had liver disease was 8. Of
these 8 respondents 7 answered correctly that they should not take Mevacor
OTC. The one that did not answer
correctly answered he/she did not know if he/she could take Mevacor OTC and
volunteered that he/she would ask a doctor.
Allergy to lovastatin:
The total number of respondents reporting that they had an allergy to
lovastatin was 3. Of these 3
respondents, 2 answered correctly that they should not take Mevacor OTC. The
one that did not answer correctly did not know if he/she could take Mevacor OTC
and volunteered that he/she would ask a doctor.
Pregnancy: The total number of respondents reporting
that they were pregnant was 4. Of these
4 respondents, all 4 answered correctly that they should not take Mevacor OTC.
Breast feeding: One
respondent reported she was breast feeding.
She answered correctly that she should not take Mevacor OTC.
Muscle problem from
prior cholesterol medication: The total number of respondents reporting that
they had a muscle problem from prior cholesterol medication was 23. Of these 23 respondents 16 (70%) answered
correctly that they should not take Mevacor OTC. Six of the 7 that did not answer correctly
answered they could use Mevacor OTC and volunteered that they would ask a
doctor. One respondent did not know and
did not volunteer to ask a doctor.
The number of
respondents who had one of the medical conditions contraindicated on the label was
small. This limits the ability to
comment, however the trend towards correct responses was good. All the respondents who answered incorrectly
volunteered that they would ask a doctor..
The question used to elicit this answer was Q12: What would you do? What
else? This probing question was a follow up to question (Q11): Assuming you
decided you were interested in trying Mevacor™OTC, is there anything that you
personally would do before starting to use it, or not; answer choices: yes, no,
wouldn’t use product, or don’t know. Because the respondents answered an open
ended question, the answers provide some insight into the respondent’s decision
making process. However, it is important
to note that nowhere under the Warning
subheading Do not use if does it state “ask a doctor”
The second subsection under the Warnings
section of the label is: “Ask your
doctor or pharmacist (study personnel) before use if you are taking”
§
Any prescription medicine: If you are taking any prescription
medicine, ask your doctor or study personnel before taking MEVACOR™OTC. Certain drugs can interact with MEVACOR™OTC
and can increase the possibility of side effects.
§
Other cholesterol-lowering medicine: DO
NOT substitute MEVACOR™OTC for your prescription or non-prescription
cholesterol-lowering medicine without talking to your doctor.
§
New Prescriptions: Tell your doctor you
are taking MEVACOR™OTC before you begin taking any new prescription
medicine.
The following tables supplied by
the sponsor provide data for respondents who self-selected correctly,
acceptably, or incorrectly based on reported medication use that the label
states “Ask your doctor or pharmacist before use if you are taking”.
These tables include: currently taking a prescription drug for cholesterol,
taking other prescription medications, or on > 1000 mg Niacin for
cholesterol (non-prescription cholesterol-lowering medicine*):
Comment:
*This is an incorrect statement in the questionnaire; Niacin is also a
prescription product.
Comment:
Currently taking a prescription
drug for cholesterol: The total number of respondents reporting that they are
currently taking a prescription drug for cholesterol was 104. Of these 104 respondents 59 (57%) answered
correctly that they should not take Mevacor OTC. Thirty three (32%) were considered to have “acceptable”
answers with 30 (29%) stating that they could use the product but volunteered
would talk to a doctor before starting Mevacor OTC and 3 (3%) stating that they
didn’t know but volunteered that they would speak to a doctor before stating
Mevacor OTC. The correct plus acceptable
responses equaled 92 (88%). Twelve (12%)
of the respondents answered incorrectly.
Taking other
prescription medications: The total number of respondents reporting that they
are taking other prescription medications was 25. Fourteen (56%) answered correctly that they
should not take Mevacor OTC. Nine (36%) were considered to have “acceptable”
answers with 7 (28%) stating that they could use the product but volunteered to
talk to a doctor before using Mevacor OTC.
Two (8%) stated they did not know but volunteered that they would speak
to a doctor before using Mevacor OTC. The correct plus acceptable responses
equaled 23 (92%). Two (8%) of the
respondents answered incorrectly.
On > 1000 mg
Niacin for cholesterol: The total number of respondents reporting that they are
taking Niacin for cholesterol was 6. Of
these 6 respondents 2 answered correctly that they should not take Mevacor
OTC. Four respondents were considered to
have “acceptable” answers with all 4 stating that they could use the product
but volunteered would talk to a doctor before starting Mevacor OTC. The correct
plus acceptable responses equaled 6 (100%).
For all of these
contraindications the label states a person should ask a doctor or pharmacist
before taking Mevacor OTC. Given that
this statement appears on the label, it is reasonable to consider answers
acceptable if the respondent volunteered that they would speak to a doctor
before taking this product.
Of interest is the
fact that 104 (15%) of the respondents reported that they were taking
prescription medication for cholesterol.
It could be assumed that they have more knowledge about cholesterol
lowering agents than the other respondents.
If their results were analyzed as a separate cohort, would they have a
higher percentage of correct answers? The sponsor did not provide this
information.
The third subheading under the Warnings
section of the label is: “Do Not use
unless directed by your doctor if you have”
§
very high LDL”bad” cholesterol 171-400 mg/dl
§
high triglycerides 200-900 mg/dl
§
healthy HDL “good” cholesterol 60-200 mg/dl
§
had a stroke
§
ever had heart disease (heart attack or angina)
§
diabetes
The following tables supplied by
the sponsor provide data for respondents who self-selected correctly,
acceptably or incorrectly based on reported medical conditions that the label
states “Do not use unless directed by
your doctor if you have”. These tables include: heart disease, stroke, and
diabetes:
Comments:
This section of the
label does not direct the consumer to ask a doctor before taking Mevacor
OTC. This section of the label specifically states not to take Mevacor OTC unless
directed by a doctor if a consumer has any of the listed medical
conditions. Although the sponsor’s
“acceptable” response (asking a doctor before taking this product) may
be considered a similar answer, it does not indicate consumer understanding
that this product should only be used under the direction of a doctor. Therefore asking a doctor before
taking this product should not be considered an acceptable answer.
Heart disease: The
total number of respondents reporting that they have heart disease was 44. Of these 44 respondents 30 (68%) answered
correctly that they should not take Mevacor OTC. Ten (23%) were considered to have “acceptable”
answers with all of them stating that they could use the product but
volunteered would talk to a doctor before starting Mevacor OTC. The correct
plus acceptable responses equaled 40 (91%).
Four (9%) of the respondents answered incorrectly.
Stroke: The total
number of respondents reporting that they have had a stroke was 27. Of these 27 respondents 19 (70%) answered
correctly that they should not take Mevacor OTC. Six (22%) were considered to have “acceptable”
answers with all of them stating that they could use the product but
volunteered would talk to a doctor before starting Mevacor OTC. The correct
plus acceptable responses equaled 25 (93%).
Two (7%) of the respondents answered incorrectly.
Diabetes: The total number of respondents reporting
that they have diabetes was 81. Of these
81 respondents 59 (73%) answered correctly that they should not take Mevacor
OTC. Eighteen (22%) were considered to
have “acceptable” answers. Fourteen
(17%) stated that they could use the product but volunteered totalk to a doctor
before starting Mevacor OTC. Four (5%) stated that they did not know but
volunteered that they would speak to a doctor before taking Mevacor OTC. The correct plus acceptable responses equaled
77 (95%). Four (5%) of the respondents
answered incorrectly.
Mevacor OTC is indicated for women age 55 or older and for
men age 45 and older. The following
tables supplied by the sponsor provide data for respondents who self-selected
correctly, acceptably or incorrectly based on age:
Comments:
Four hundred three
male and female respondents were younger than the target age to take Mevacor
OTC. Seventy-two to 82% of them made a
correct self-selection decision based on age.
The total number of
respondents in the target age range was 293.
Forty-four-60% of them made a correct self-selection decision based on
age
The fact that about
half of the respondents in the appropriate age range did not understand that
they could take this product may be the result of where the age information is
located on the label. This could also be
due to difficulties that an older population has in acquiring information on
OTC labels, especially when the print is small as previously mentioned.1
Self-section errors
based on age for in the younger female population is of particular concern due
to the Pregnancy Category X status of lovastatin.
1 Wogalter, MS, & Vigilante, WJ. 2003. Effects of label format on knowledge acquisition and perceived readability by younger and older adults, Ergonomics, 46(4), 327-344.
The total number of respondents who stated they could use
Mevacor OTC right away (Q10) was 209.
The following table provides data on those who responded correctly when all
self-selection categories were analyzed against the medical history questions
(Q39-75)
Comment:
This table reveals
that only 1% of the respondents who stated that they could use Mevacor OTC
right away self-selected correctly. It
is concerning that the sponsor relies on “acceptable” answers, which involves
talking to a doctor, as criteria for comprehension. This is not consistent with the concept of
OTC self-selection. These “acceptable”
answers push Mevacor OTC into a quasi prescription drug status.
The sponsor describes that the following table represents
the 33 respondents who stated that the only reason for not being able to start
taking Mevacor OTC “today” was because they did not know their cholesterol
numbers (Q10). The respondents were then
asked whether they could start using Mevacor OTC if their numbers were in the
appropriate range (Q14). Table 13
provides the results of this analysis:
Comment:
Of the 14 (42%) respondents who said they could start using Mevacor OTC
today if they knew that their cholesterol numbers were in the appropriate
range, only 5 (15%) were correct based on their medical
The following statement and table submitted by the sponsor describes the sponsor’s attempt to understand why respondents self-selected incorrectly:
Comment:
It is difficult to make any comments based on these findings given the
small sample size (12). It is unclear
why the sponsor did not ask more respondents this question. According to Table 30. 59 respondents self-selected incorrectly and
an additional 147 respondents gave the wrong answer but said they would check
with a doctor. Questioning a larger
sample size may have provided useful information.
Summary
Taking into account only “correct”
responses, and not “acceptable” respondents
demonstrated reasonable comprehension of the following communication
objectives:
·
Comprehension of what condition the product is
to be used for
·
Dosage information
·
Active ingredient in the product
·
Understanding that evening is the best time of
day to take it
·
Scenarios that address prerequisites for using
the product, specifically diet, exercise, and appropriate time frame for
testing cholesterol in order to decide whether or not to use the product
· Other medications (good comprehension for prescription medications; poor comprehension for non-prescription medications) that require consultation with a health care professional prior to product use or preclude use.
·
Scenarios
that address comprehension of the timing for follow-up cholesterol testing
Taking into account only “correct” responses and not “acceptable” responses, all respondents demonstrated lower comprehension of the following communication objectives:
· Determine how well respondents correctly respond to questions designed to try to measure self-selection. Ninety nine percent of all the respondents who reported that they could start Mevacor OTC right away, selected incorrectly.
· Other medical conditions that require consultation with a health care professional prior to product use or preclude use
· Scenarios that describe events that might occur during product usage that should indicate that they need to stop using the product and/or talk with a doctor
·
Scenarios that describe combinations of age,
gender, cholesterol levels, risk factors, and other factors that should alert
respondents to talk to their doctors before using the product or to not use it
at all
·
Understanding that a person’s cholesterol level
will go back up if someone stops using the product
· Scenarios that explore comprehension of the goal message
One percent of the respondents who
stated they could use Mevacor OTC “right away” actually self-selected correctly
for all communication objectives. Ninety-nine
percent of all the respondents who reported that they could start Mevacor OTC
right away, self-selected incorrectly because of an incorrect response for at
least one communication objective.
Of final note, several of the
tables supplied by the sponsor had incorrect number of respondents in some of
the columns and incorrect percentage calculations; however, they were
relatively insignificant and did not impact the outcome of this review.